logo-loader

Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks

Last updated: 14:17 07 Apr 2020 EDT, First published: 14:56 07 Apr 2020 EDT

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive about their other drug, this one for post-surgery pain, ATB-352 and what the next steps are in its development

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the next...

on 12/8/20